Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Elizabeth Hester

Physician Assistant North Chesterfield, VA Physician Assistant

NPI 1205219573 CMS profile 10429055

8110 Midlothian Tpke, North Chesterfield, VA 23235

Open in the dashboard

General payments

$10,245

315 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Elizabeth Hester of North Chesterfield, VA is reported in the CMS Open Payments database as having received $10,245 across 315 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,051 106
2024 General $5,168 62
2023 General $1,342 79
2022 General $675 25
2021 General $1,009 43

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Elizabeth Hester
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Elizabeth Hester were reported at $2,051. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Elizabeth Hester Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $1,009 $132 $37–$438 $132
2022 $675 $155 $48–$522 $149
2023 $1,342 $167 $52–$557 $160
2024 $5,168 $178 $55–$600 $164
2025 $2,051 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Verrica Pharmaceuticals Inc. $4,347 12 payments
  2. Janssen Biotech, Inc. $1,136 45 payments
  3. AbbVie, Inc. $787 45 payments
  4. Genzyme Corporation $543 22 payments
  5. Arcutis Biotherapeutics, Inc. $502 64 payments
  6. Novartis Pharmaceuticals Corporation $401 17 payments
  7. Pfizer Inc. $341 19 payments
  8. Incyte Corporation $320 14 payments
  9. Sun Pharmaceutical Industries Inc. $258 9 payments
  10. LEO Pharma Inc. $214 10 payments
  11. Other $1,397 58 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $5,474 300 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $3,500 4 payments
  3. Education $773 10 payments
  4. Travel and Lodging $498 1 payment
Products named General payments · program years 2021–2025
  1. YCANTH $4,347 12 payments
  2. TREMFYA $1,247 46 payments
  3. DUPIXENT Immunology $947 34 payments
  4. RINVOQ $389 19 payments
  5. Zoryve $371 45 payments
  6. CIBINQO $341 19 payments
  7. OPZELURA $320 14 payments
  8. EUCRISA $243 16 payments
  9. DUPIXENT Inflammation And Immunology $229 7 payments
  10. ADBRY $214 10 payments
  11. Other $2,239 116 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 18 drugs

Part D claims

601

Median for Physician Assistant: 241

Drug cost

$211,000

Median for Physician Assistant: $4,110

Branded share of claims

7.5%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Humira(Cf) Pen Adalimumab Brand 21 $145,102
Dupixent Syringe Dupilumab Brand 12 $52,913
Clobetasol Propionate Generic 120 $4,450
Fluorouracil Generic 17 $1,348
Doxycycline Hyclate Generic 56 $1,011
Ketoconazole Generic 56 $931
Clindamycin Phosphate Generic 35 $896
Betamethasone Dipropionate Generic 23 $758
Triamcinolone Acetonide Generic 85 $754
Metronidazole Generic 15 $680

The 10 drugs with the highest cost, of 18 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 31 billing codes

Paid by Medicare

$81,789

Medicare's payments for the services billed

Medicare patients

548

Average age 73

Services billed

2,875

331 women, 217 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 68%
Arthritis 39%
Diabetes 26%
Ischemic heart disease 23%
Depression 18%
Atrial fibrillation 15%
Chronic kidney disease 15%
Cancer 15%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 16 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
YCANTH
  • VERRICA PHARMACEUTICALS INC. $4,240
$4,240 — —
TREMFYA
  • Janssen Biotech, Inc. $259
$259 — —
Zoryve
  • Arcutis Biotherapeutics, Inc. $162
$162 — —
Otezla
  • Amgen Inc. $97
$97 — —
DUPIXENT
  • GENZYME CORPORATION $90
$90 12 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 16 in the dashboard with a free account

Records

315 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Virginia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record